ArticleCancers2026
Impact of 18F-DCFPyL-PSMA PET/CT on Radiotherapy Planning and Treatment Intensification in Occult Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy.
Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biochemical recurrence (BCR) after radical prostatectomy (RP) frequently occurs despite negative conventional imaging, making salvage treatment decisions challenging. We evaluated the impact of 18F-DCFPyL-PSMA PET/CT on disease detection and radiotherapy planning in patients with occult BCR.
methodsWe conducted a prospective single-center observational study including 85 patients with BCR after RP, negative or inconclusive conventional imaging, and PSA levels between 0.2 and 1.0 ng/mL or persistent PSA after previous local treatment. Detection rates (DRs) were evaluated according to PSA level, PSA doubling time (PSA-DT), and International Society of Urological Pathology (ISUP) grade. Changes in radiotherapy planning and treatment intensification were assessed by comparing intended management before and after PSMA PET/CT.
resultsPSMA PET/CT detected recurrent disease in 53% of patients. DRs increased significantly with PSA level, reaching 31.3% for PSA 0.2-0.5 ng/mL, 60.0% for PSA 0.5-0.9 ng/mL, and 77.8% for PSA 1.0 ng/mL (
conclusions18F-DCFPyL-PSMA PET/CT provides clinically meaningful information beyond disease detection by substantially modifying radiotherapy planning and treatment selection in patients with occult BCR after RP. These findings support the integration of molecular imaging into salvage treatment planning to enable more personalized, biology-driven radiotherapy strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.